Clinical Trial Update: Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is planned to evaluate adjunctive rifaximin for preventing radiotherapy-induced diarrhea in cancer patients, including prostate, cervical, bla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cervical Cancer
• Prostate Cancer
• Radiation Enteritis
• Rectal Cancer

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Mansoura University | Conditions: Radiotherapy Induced Diarrhea, Acute Radiation Enteritis | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING